Portal de Periódicos da CAPES

Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme

2012; Elsevier BV; Volume: 63; Issue: 6 Linguagem: Inglês

10.1016/j.eururo.2012.08.058

1873-7560

Axel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, Christian Arsov, Margitta Retz, Stefan C. Müller, Peter Albers, Jürgen E. Gschwend, Manfred P. Wirth, Ursula Steiner, Kurt Miller, Elmar Heinrich, Lutz Trojan, Björn Volkmer, Friedhelm Honecker, Carsten Bokemeyer, Bastian Keck, Burkhard Otremba, Evelyne Ecstein-Fraïsse, David Pfister,

Cancer Immunotherapy and Biomarkers

Cabazitaxel (Cbz) is an approved second-line treatment in metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy with a significant survival benefit compared with mitoxantrone. However, grade 3/4 toxicities were reported in 82% of patients. To report on the safety results of mCRPC patients treated within a compassionate-use programme in Germany. A total of 111 patients with a mean age of 67.9 yr (range: 49–81 yr) and progressive mCRPC were included. Patients had received a mean number of 12.7 ± 10.8 cycles (range: 6–69 cycles) of docetaxel with a mean cumulative dose of 970.9 mg/m2; mean time from last docetaxel application to progression was 6.95 mo (range: 2–54 mo). Of the patients, 31.5% progressed by prostate-specific antigen (PSA) increase only; the remainder had a combination of PSA increase and clinical progression. Cbz at a dosage of 25 mg/m2 intravenously every 3 wk combined with 5 mg of oral prednisone twice a day. Treatment-associated toxicity was the primary study end point; progression-free and overall survival were secondary end points. A descriptive statistical analysis was performed. Patients received a mean number of 6.5 ± 2.2 cycles of Cbz and a mean cumulative dose of 160.3 ± 51.5 mg/m2. Grade 3 and 4 treatment-emergent adverse events were recorded in 34 patients (30.6%) and 18 patients (16.2%), respectively. Grade 3/4 anaemia, neutropenia, and thrombocytopenia were reported in 4.5%, 7.2%, and 0.9% of the patients, respectively. Neutropenic fever was reported in 1.8% of the patients. Grade 3/4 gastrointestinal toxicity was identified in 4.5% of the patients. Three patients died because of Cbz-related toxicity. Granulocyte colony-stimulating growth factors were used in 17.1% of patients. The limitations are due to the nonrandomised nature of the trial. Treatment with Cbz is tolerable and is associated with a low incidence of serious adverse events in a real-world patient population with CRPC. The outcome of serious adverse events can be minimised with proactive treatment management and conscientious monitoring.